NEW YORK, Sept. 2 (GenomeWeb News) - SIDMAP, a Los Angeles-based startup, on Wednesday introduced a metabolic profiling technology service based on a proprietary tracer-molecule technology and mass spectrometry.
The company, named after its Stable Isotope-based Dynamic Metabolic Profiling technology, is commercializing the approach as a service targeting drug discovery and development. The SIDMAP technology uses labeled metabolic substrate molecules (tracers) to track disease-characteristic metabolic pathways.
The technology was developed at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center by Laszlo Boros, an associate professor of pediatrics at the University of California, Los Angeles, and Paul Lee, UCLA professor of pediatrics, the company said in a statement.
SIDMAP has licensed the technology from LA Biomed. Financial details of the agreement were not disclosed, the company said.